[Home ] [Archive]   [ فارسی ]  
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
Main Menu
Home::
Journal Information::
About the Journal
Editorial Board
Aims& Scopes
Journal News
Articles archive::
All Issues
Current Issue
Browse by Authors
Browse by Keywords
Publication Ethics::
Peer Review Process::
Indexing Databases::
For Authors::
Authors Guideline
Call for Papers
Submission Instruction
Review Process
Research Ethics Statements
Ethical issues
Author Complaint Process
For Reviewers::
Reviewers Section
Subscription::
Registration Information
Subscription Form
Contact us::
Contact Information
Contact us
Site Facilities::
Site map
Search contents
FAQ
Top 10 contents
Inform to friends
::
Google Scholar Metrics

Citation Indices from GS

AllSince 2021
Citations83693836
h-index3119
i10-index24387
..
Search in website

Advanced Search
..
Receive site information
Enter your Email in the following box to receive the site news and information.
..
Registered in

AWT IMAGE

AWT IMAGE
..
:: Volume 34, Issue 3 (7-2026) ::
Journal of Ilam University of Medical Sciences 2026, 34(3): 85-94 Back to browse issues page
Evaluation of Interleukin-38 Serum Levels in Patients with Placenta Accreta
Enayat Anvari1 , Moslem Ahmadi2 , Masoume Naseri1 , Najmeh Rokhtabnak2 , Atefe Ghamar Talepoor2 , Mohammad Ali-Hassanzadeh3 , Behrouz Gharesi-Fard *4 , Kurosh Kalantar5
1- Dept of physiology, Faculty of Medicine, Ilam University of Medical Sciences, Ilam, Iran
2- Dept of Immunology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
3- Dept of Immunology, School of Medicine, Jiroft University of Medical Sciences, Jiroft, Iran
4- Dept of Immunology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran & Infertility Research Center, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran , gharesifb@sums.ac.ir
5- Department of Immunology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
Abstract:   (121 Views)
Introduction:  Placenta accreta is one of the life-threatening pregnancy-related disorders. Placenta accreta is generally described by extreme placentation and penetration of the placenta into the myometrium. There are increasing data regarding the role of the immune system in the induction of placenta accreta. IL-38 is a recently introduced member of the IL-1 cytokine family, which may play a role in the regulation of inflammatory response. This study aimed to investigate the serum level of IL-38 in patients complicated with placenta accreta.
Materials & Methods: A total of 50 women, including 23 women with placenta accreta, 13 healthy pregnant women, and 14 non-pregnant women, were enrolled in this study. Clinical and demographic data were recorded for all cases. The quantitative serum levels of IL-38 were measured using the ELISA method.
Results: The serum levels of IL-38 were significantly higher in non-pregnant cases compared to women complicated with placenta accreta as well as normal pregnant women (62.88±23.58 vs. 25.41±26.84 and 10.04±7.22, respectively; p-value < 0.001 for both comparisons), while there were no statistical differences between normal pregnant women and women diagnosed with placenta accreta regarding IL-38 serum levels (p = 0.2).
Conclusion: Based on the results of the present study, the lower levels of IL-38 in the patients with placenta accreta indicate the lack of compensatory response toward the high level of angiogenesis stimuli and trophoblast invasion during this disease.
Keywords: Interleukin-38, Pregnancy, Placenta accreta
Full-Text [PDF 740 kb]   (42 Downloads)    
Editorial Note: Applicable | Subject: immunology
Received: 2026/02/14 | Accepted: 2026/05/6 | Published: 2026/07/27
References
1. Jauniaux E, Burton GJ. Pathophysiology of placenta accreta spectrum disorders: a review of current findings. Clin Obstet Gynecol. 2018; 61:743-54.doi: 10.1097/GRF.0000000000000392.
2. Hecht JL, Karumanchi SA, Shainker SA. Immune cell infiltrate at the utero-placental interface is altered in placenta accreta spectrum disorders. Arch Gynecol Obstet. 2020; 301: 499-507. doi: 10.1007/s00404-020-05453-1.
3. Mor G, Cardenas I. The immune system in pregnancy: a unique complexity. Am J Reprod Immunol. 2010; 63: 425-33. doi: 10.1111/j.1600-0897.2010.00836.x.
4. Orsi N, Tribe R. Cytokine networks and the regulation of uterine function in pregnancy and parturition. J Neuroendocrinol. 2008; 20: 462-9. doi: 10.1111/j.1365-2826.2008.01668.x.
5. Batebi A, Namavar-Jahromi B, Ali-Hassanzadeh M, Ahmadi M, Hosseini MS, Gharesi-Fard B. Evaluation of IL-17 and IL-35 serum levels in patients with preeclampsia. J Reprod Infertil. 2019; 20: 237-243.
6. Chu M, Tam LS, Zhu J, Jiao D, Cai Z, Dong J, et al. In vivo anti-inflammatory activities of novel cytokine IL-38 in Murphy Roths Large (MRL)/lpr mice. Immunobiology. 2017; 222: 483-93. doi: 10.1016/j.imbio.2016.10.012.
7. Ge Y, Huang M, Wu Y, Dong N, Yao YM. Interleukin‐38 protects against sepsis by augmenting immunosuppressive activity of CD4+ CD25+ regulatory T cells. J Cell Mol Med. 2020; 24: 2027-39. doi: 10.1111/jcmm.14902.
8. Boutet M-A, Nerviani A, Pitzalis C. IL-36, IL-37, and IL-38 cytokines in skin and joint inflammation: a comprehensive review of their therapeutic potential. Int J Mol Sci. 2019; 20: 1257. doi: 10.3390/ijms20061257.
9. Akdis M, Aab A, Altunbulakli C, Azkur K, Costa RA, Crameri R, et al. Interleukins (from IL-1 to IL-38), interferons, transforming growth factor β, and TNF-α: Receptors, functions, and roles in diseases. J Allergy Clin Immunol. 2016; 138: 984-1010. doi: 10.1016/j.jaci.2016.06.033.
10. Han Y, Mora J, Huard A, da Silva P, Wiechmann S, Putyrski M, et al. IL-38 ameliorates skin inflammation and limits IL-17 production from γδ T cells. Cell Rep. 2019; 27: 835-46. e5. doi: 10.1016/j.celrep.2019.03.082.
11. Southcombe J, Redman C, Sargent I, Granne I. Interleukin‐1 family cytokines and their regulatory proteins in normal pregnancy and pre‐eclampsia. Clin Exp Immunol. 2015; 181: 480-90. doi: 10.1111/cei.12608.
12. Shainker SA, Silver RM, Modest AM, Hacker MR, Hecht JL, Salahuddin S, et al. Placenta accreta spectrum: biomarker discovery using plasma proteomics. Am J Obstet Gynecol. 2020; 223: 433.e1-.e14. doi: 10.1016/j.ajog.2020.03.019.
13. Hecht JL, Karumanchi SA. Immune cell infiltrate at the utero-placental interface is altered in placenta accreta spectrum disorders. Arch Gynecol Obstet. 2020; 301: 499-507. doi: 10.1007/s00404-020-05453-1.
14. Gomez-Lopez N, StLouis D, Lehr MA, Sanchez-Rodriguez EN, Arenas-Hernandez M. Immune cells in term and preterm labor. Cell Mol Immunol. 2014; 11: 571-81. doi: 10.1038/cmi.2014.46.
15. Laresgoiti-Servitje E. A leading role for the immune system in the pathophysiology of preeclampsia. J Leukoc Biol. 2013; 94: 247-57. doi: 10.1189/jlb.1112603.
16. Raghupathy R. Cytokines as key players in the pathophysiology of preeclampsia. Med Princ Pract. 2013; 22: 8-19. doi: 10.1159/000354200.
17. Southcombe JH, Redman CW, Sargent IL, Granne I. Interleukin-1 family cytokines and their regulatory proteins in normal pregnancy and pre-eclampsia. Clin Exp Immunol. 2015;181: 480-90. doi: 10.1111/cei.12608. Epub 2015 Jun 29.
18. Clavel G, Thiolat A, Boissier MC. Interleukin newcomers creating new numbers in rheumatology: IL-34 to IL-38. Joint Bone Spine. 2013; 80: 449-53. doi: 10.1016/j.jbspin.2013.04.014.
19. Khamoushi T, Ahmadi M, Ali-Hassanzadeh M, Zare M, Hesampour F, Gharesi-Fard B, et al. Evaluation of Transforming Growth Factor-β1 and Interleukin-35 Serum Levels in Patients with Placenta Accreta. Lab Med. 2021;52: 245-9. doi: 10.1093/labmed/lmaa071.
20. Duzyj CM, Buhimschi IA, Laky CA, Cozzini G, Zhao G, Wehrum M, et al. Extravillous trophoblast invasion in placenta accreta is associated with differential local expression of angiogenic and growth factors: a cross-sectional study. BJOG. 2018; 125: 1441-8. doi: 10.1111/1471-0528.15176.
21. Schwede S, Alfer J, von Rango U. Differences in regulatory T-cell and dendritic cell pattern in decidual tissue of placenta accreta/increta cases. Placenta. 2014; 35: 378-85. doi: 10.1016/j.placenta.2014.03.004.
22. Takenaka S-i, Kaieda S, Kawayama T, Matsuoka M, Kaku Y, Kinoshita T, et al. IL-38: a new factor in rheumatoid arthritis. Biochem Biophys Rep. 2015; 4: 386-91. doi: 10.1016/j.bbrep.2015.10.015.
23. Rudloff I, Godsell J, Nold‐Petry CA, Harris J, Hoi A, Morand EF, et al. Brief report: interleukin‐38 exerts antiinflammatory functions and is associated with disease activity in systemic lupus erythematosus. Arthritis Rheumatol. 2015; 67: 3219-25. doi: 10.1002/art.39328.
24. Boutet MA, Bart G, Penhoat M, Amiaud J, Brulin B, Charrier C, et al. Distinct expression of interleukin (IL)‐36α, β and γ, their antagonist IL‐36Ra and IL‐38 in psoriasis, rheumatoid arthritis and Crohn's disease. Clin Exp Immunol. 2016; 184: 159-73. doi: 10.1111/cei.12761.
25. Li J, Liu L, Rui W, Li X, Xuan D, Zheng S, et al. New interleukins in psoriasis and psoriatic arthritis patients: the possible roles of interleukin-33 to interleukin-38 in disease activities and bone erosions. Dermatology. 2017; 233: 37-46. doi: 10.1159/000471798.
26. de Graaf DM, Jaeger M, van den Munckhof IC, Ter Horst R, Schraa K, Zwaag J, et al. Reduced concentrations of the B cell cytokine interleukin 38 are associated with cardiovascular disease risk in overweight subjects. Eur J Immunol. 2021;51: 662-71. doi: 10.1002/eji.201948390.
27. Yu Z, Liu J, Zhang R, Huang X, Sun T, Wu Y, et al. IL-37 and 38 signalling in gestational diabetes. J Reprod Immunol. 2017;124: 8-14. doi: 10.1016/j.jri.2017.09.011.
28. Mora J, Schlemmer A, Wittig I, Richter F, Putyrski M, Frank AC, et al. Interleukin-38 is released from apoptotic cells to limit inflammatory macrophage responses. J Mol Cell Biol. 2016; 8: 426-38. doi: 10.1093/jmcb/mjw006.
29. Zhang J, Zhao R, Chen J, Jin J, Yu Y, Tian Y, et al. The Effect of Interleukin 38 on Angiogenesis in a Model of Oxygen-induced Retinopathy. Sci Rep. 2017; 7: 2756. doi: 10.1038/s41598-017-03079-z.
Send email to the article author

Add your comments about this article
Your username or Email:

CAPTCHA

Ethics code: IR.MEDILAM.REC.1399.215

XML   Persian Abstract   Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Anvari E, Ahmadi M, Naseri M, Rokhtabnak N, Ghamar Talepoor A, Ali-Hassanzadeh M, et al . Evaluation of Interleukin-38 Serum Levels in Patients with Placenta Accreta. J. Ilam Uni. Med. Sci. 2026; 34 (3) :85-94
URL: http://sjimu.medilam.ac.ir/article-1-8905-en.html
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 34, Issue 3 (7-2026) Back to browse issues page
مجله دانشگاه علوم پزشکی ایلام Journal of Ilam University of Medical Sciences
Persian site map - English site map - Created in 0.16 seconds with 39 queries by YEKTAWEB 4766